🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 69 of 151

  1. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  2. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  3. JEMPERLI 500 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 2 small molecule active

    1 trial

  4. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  5. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    Fondazione Telethon ETS

    HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  6. JIN-A02

    INTENSITY THERAPEUTICS, INC.

    EGFR Mutant Advanced Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. JMKX000623

    Jemincare

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  8. JMT108

    Shanghai University of Traditional Chinese Medicine

    Unresectable Locally Advanced or Metastatic Melanoma

    phase 2 small molecule active

    1 trial

  9. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder

    phase 2 small molecule active

    1 trial

  10. JNJ-17000139, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma of the Bladder

    phase 2 small molecule active

    1 trial

  11. JNJ-40411813

    Janssen Cilag International NV

    Focal Onset Seizures

    phase 2 small molecule completed

    1 trial

  12. JNJ-42756493, JNJ-42756493, JNJ-42756493

    Janssen-Cilag International N.V.

    Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.

    phase 2 small molecule active

    1 trial

  13. JNJ-54767414, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Dexamethasone Tablets BP 2.0mg, FLUDARABINE , Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, JNJ-68284528, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Accord 15 mg hard c

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. JNJ-61186372, JNJ-63723283, JNJ-63723283

    Janssen-Cilag International N.V.

    Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. JNJ-63723283, JNJ-42756493, JNJ-42756493, JNJ-42756493

    Tour Hekla

    Muscle-invasive bladder cancer (MIBC)

    phase 2 small molecule active

    1 trial

  16. JNJ-64281802

    Janssen Cilag International NV

    Dengue

    phase 2 small molecule terminated

    2 trials

  17. JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  18. JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. JNJ-73763989

    Janssen Cilag International NV

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  20. JNJ-73841937, JNJ-61186372

    Janssen-Cilag International N.V.

    Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  22. JNJ-73841937, Montelukast Sodium Tablets, Dexamethason 4 mg JENAPHARM®, Methotrexat-Ebewe, 10mg/ml, roztwór do wstrzykiwań, JNJ-61186372, Methotrexate

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

    Janssen-Cilag International N.V.

    Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  24. JNJ-77242113

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  25. JNJ-79635322, JNJ-79635322

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule active

    1 trial

  26. JNJ-80202135, JNJ-80202135, Saline, 0.9% Sodium Chloride Solution for Injection

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  27. JNJ-81241459, JNJ-81241459 200mg, placebo tablet, JNJ-81241459, JNJ-81241459 50mg, placebo tablet

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  28. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  29. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  30. JNT-517 Suspension

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

  31. JS004

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

  33. JY231 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  34. JZP-110

    Jazz Pharmaceuticals Ireland Limited

    Excessive Sleepiness

    phase 2 small molecule completed

    1 trial

  35. JZP150

    Jazz Pharmaceuticals Ireland Limited

    Post Traumatic Stress Disorder

    phase 2 small molecule completed

    1 trial

  36. JZP3507

    Jazz Pharmaceuticals Ireland Limited

    Meningioma

    phase 2 small molecule active

    1 trial

  37. JZP385

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  38. JZP541

    Jazz Pharmaceuticals Ireland Limited

    Irritability Associated With Autism Spectrum Disorder

    phase 2 small molecule terminated

    1 trial

  39. JZP598

    Ningbo Cancer Hospital

    Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, colorectal, head & neck or sarcoma) or HER2 mutant non-small cell lung cancer.

    phase 2 small molecule active

    1 trial

  40. JZP598

    Jazz Pharmaceuticals Ireland Limited

    Patients with HER2-expressing solid tumors

    phase 2 small molecule active

    1 trial

  41. JZP598, TRASTUZUMAB EMTANSINE, DOCETAXEL , TRASTUZUMAB , PACLITAXEL , PACLITAXEL ALBUMIN-BOUND, PERTUZUMAB , CARBOPLATIN , TRASTUZUMAB EMTANSINE

    Jazz Pharmaceuticals Ireland Limited

    HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  42. Jakavi 10 mg tablets, Jakavi 10 mg tablets, Jakavi 20 mg tablets, Jakavi 5 mg tablets, elritercept, Jakavi 20 mg tablets, Jakavi 20 mg tablets, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets

    Takeda

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  43. Jakavi 15 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 20 mg tablets

    Pari Pharma GmbH

    haemophagocytic lymphohistiocytosis (HLH) in children

    phase 2 small molecule active

    1 trial

  44. Jakavi 15 mg tablets, Placebo of Jakavi 15mg

    Pari Pharma GmbH

    Inclusion body Myositis

    phase 2 small molecule active

    1 trial

  45. Jakavi 5 mg tablets, Jakavi 15 mg tablets

    Incyte

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  46. Jakavi 5 mg tablets, Venetoclax, Jakavi 20 mg tablets, Venetoclax, Jakavi 10 mg tablets, Venetoclax, Venetoclax, Venetoclax, Venetoclax, Jakavi 15 mg tablets

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  47. Jardiance 10 mg film-coated tablets, BI 690517, Spironolacton Accord 25 mg filmomhulde tabletten, OMNIPAQUE 350 mg I/ml., AMINOHIPPURIC ACID

    Disc Medicine

    Heart failure, cardiovascular disease, chronic kidney disease

    phase 2 small molecule active

    1 trial

  48. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.